The role of filgotinib in ulcerative colitis and Crohn's disease

Immunotherapy. 2023 Nov 27. doi: 10.2217/imt-2023-0116. Online ahead of print.


Jacopo Fanizza 1Ferdinando D'Amico 1 2Gaetano Lauri 1Samuel J Martinez-Dominguez 3Mariangela Allocca 1Federica Furfaro 1Alessandra Zilli 1Gionata Fiorino 1Tommaso Lorenzo Parigi 1Simona Radice 1Laurent Peyrin-Biroulet 4 5Silvio Danese 1


Author information

1Department of Gastroenterology & Endoscopy, IRCCS San Raffaele Hospital & Vita-Salute San Raffaele University, Milan, Italy.

2Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.

3Department of Gastroenterology, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain; Aragón Health Research Institute, Zaragoza, Spain; School of Medicine, University of Zaragoza, Spain.

4University of Lorraine, Inserm, NGERE, F-54000 Nancy, France.

5Department of Gastroenterology, Nancy University Hospital, F-54500 Vandœuvre-lès-Nancy, France.


Filgotinib is an oral small molecule that selectively inhibits JAK1. It is already approved for the treatment of moderately to severely active ulcerative colitis (UC). Ongoing studies are evaluating the efficacy and safety of filgotinib in Crohn's disease (CD). The purpose of this review is to summarize the available data regarding filgotinib in the management of UC and CD. We used Pubmed, Embase and clinicaltrials.gov websites to search all available data and currently ongoing studies regarding the efficacy and safety of filgotinib in inflammatory bowel diseases. Filgotinib is an effective and safe drug for the management of biologic-naive and biologic-experienced patients with moderate-to-severe UC. The same efficacy results have not been achieved in CD.

© Copyright 2013-2024 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.